Abstract
Pathophysiology of idiopathic Parkinsons disease (PD) is associated with degeneration of dopaminergic neurons and inflammatory responses in the mid-brain substantia nigra (SN). However, central dopaminergic replenishment therapeutic strategy with L-3,4-dihydroxyphenylalanine (L-DOPA), the precursor for dopamine synthesis, does not fully rescue these cells in SN or improve motor function. Besides, prolonged use of L-DOPA worsens the clinical symptoms in PD patients. Thus, there is a possibility that other areas of central nervous system may also be affected in this disease. Spinal cord, the final coordinator of movement in the central nervous system, may be one such site that is critically affected during pathogenesis of this complex movement disorder. In this review, we summarize the evidence in support of involvement of calpain, a Ca2+-activated non-lysosomal protease, in spinal cord degeneration in two models of experimental parkinsonism induced by the neurotoxin 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine and also the environmental toxin rotenone. The key focus of this review is to discuss the role that calpain plays in disrupting the structural and functional integrity of the spinal cord in these experimental models of parkinsonism. A similar disruptive role of calpain has been reported earlier in SN of PD patients as well as in experimental PD animals. Studies in rodent and cell culture models of PD suggest that treatment with calpain inhibitors (e.g., calpeptin, MDL-28170) can prevent neuronal death and restore functions. Furthermore, the degradation of calpain substrates in both brain and spinal cord during pathogenesis of PD suggested a putative role of calpain, and calpain inhibition as a therapeutic strategy in PD.
Keywords: Calpain, experimental parkinsonism, MPTP, Parkinson's disease, rotenone, spinal cord
CNS & Neurological Disorders - Drug Targets
Title: Calpain as a Potential Therapeutic Target in Parkinsons Disease
Volume: 7 Issue: 3
Author(s): Supriti Samantaray, Swapan K. Ray and Naren L. Banik
Affiliation:
Keywords: Calpain, experimental parkinsonism, MPTP, Parkinson's disease, rotenone, spinal cord
Abstract: Pathophysiology of idiopathic Parkinsons disease (PD) is associated with degeneration of dopaminergic neurons and inflammatory responses in the mid-brain substantia nigra (SN). However, central dopaminergic replenishment therapeutic strategy with L-3,4-dihydroxyphenylalanine (L-DOPA), the precursor for dopamine synthesis, does not fully rescue these cells in SN or improve motor function. Besides, prolonged use of L-DOPA worsens the clinical symptoms in PD patients. Thus, there is a possibility that other areas of central nervous system may also be affected in this disease. Spinal cord, the final coordinator of movement in the central nervous system, may be one such site that is critically affected during pathogenesis of this complex movement disorder. In this review, we summarize the evidence in support of involvement of calpain, a Ca2+-activated non-lysosomal protease, in spinal cord degeneration in two models of experimental parkinsonism induced by the neurotoxin 1-methyl-4-phenyl 1,2,3,6-tetrahydropyridine and also the environmental toxin rotenone. The key focus of this review is to discuss the role that calpain plays in disrupting the structural and functional integrity of the spinal cord in these experimental models of parkinsonism. A similar disruptive role of calpain has been reported earlier in SN of PD patients as well as in experimental PD animals. Studies in rodent and cell culture models of PD suggest that treatment with calpain inhibitors (e.g., calpeptin, MDL-28170) can prevent neuronal death and restore functions. Furthermore, the degradation of calpain substrates in both brain and spinal cord during pathogenesis of PD suggested a putative role of calpain, and calpain inhibition as a therapeutic strategy in PD.
Export Options
About this article
Cite this article as:
Samantaray Supriti, Ray K. Swapan and Banik L. Naren, Calpain as a Potential Therapeutic Target in Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2008; 7 (3) . https://dx.doi.org/10.2174/187152708784936680
DOI https://dx.doi.org/10.2174/187152708784936680 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Anti-Cancer Agents in Medicinal Chemistry Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Commentary 1 (Research Highlights: Parkinson’s Disease and α-Synuclein: Passing it on)
CNS & Neurological Disorders - Drug Targets Evaluation of Assam Bora Rice Starch as Plasma Volume Expander by Polymer Analysis
Current Drug Delivery Fluorogold Induces Persistent Neurological Deficits and Circling Behavior in Mice Over-Expressing Human Mutant Tau
Current Neurovascular Research New Approaches in Drug Delivery Systems: Application for Diabetes Treatment
Infectious Disorders - Drug Targets Molecular Determinants of Enzyme Cold Adaptation: Comparative Structural and Computational Studies of Cold- and Warm-Adapted Enzymes
Current Protein & Peptide Science Therapeutic Potential of Mucoadhesive Drug Delivery Systems - An Updated Patent Review
Recent Patents on Drug Delivery & Formulation Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals From Treatment Adherence to Advanced Shared Decision Making: New Professional Strategies and Attitudes in Mental Health Care
Current Clinical Pharmacology Recent Patents on Wireless Capsule Endoscopy
Recent Patents on Biomedical Engineering (Discontinued) Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Non-Ceruloplasmin Copper Distinguishes A Distinct Subtype of Alzheimer’s Disease: A Study of EEG-Derived Brain Activity
Current Alzheimer Research Prevalence of Tooth Wear in Primary Dentition in School Children of Abu Dhabi, UAE
Applied Clinical Research, Clinical Trials and Regulatory Affairs Machine Learning, Molecular Modeling, and QSAR Studies on Natural Products Against Alzheimer’s Disease
Current Medicinal Chemistry Chromosome 17 in Fronto Temporal Lobak Degeneration (FTLD): From MAPT to Progranulin and Back
Current Alzheimer Research Transcranial Direct Current Stimulation for Treatment of Alzheimer’s Disease: A Systematic Review of Randomized Clinical Trial
Current Psychiatry Reviews Unveiling the Role of Nuclear Transport in Epithelial-to-Mesenchymal Transition
Current Cancer Drug Targets Reorganizing Metals: the Use of Chelating Compounds as Potential Therapies for Metal-Related Neurodegenerative Disease
Current Topics in Medicinal Chemistry Nanofiber Scaffolds for Treatment of Spinal Cord Injury
Current Medicinal Chemistry